Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 377 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR When Cancer Isn’t Your Only Challenge: How I Learned to Cope March 24, 2022 FDA Approves Pralsetinib for RET-Altered Thyroid Cancers December 2, 2020 EMA Recommends Extension of Indications for Ribociclib to Include Use in... November 5, 2024 Coming Full Circle on Cancer and Extrachromosomal DNA May 10, 2023 Load more HOT NEWS Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... GPRC5D Is An Active Immunotherapeutic Target in Multiple Myeloma Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and...
